Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine the effect of AIN457 (10 mg/kg i.v.) administered week 0, 2, 4, 8, 12, 16 and 20 compared to placebo on the number of combined unique active lesions (CUAL) observed on brain MRI scans performed every 4th week from week 4 to week 24 in patients with relapsing-remitting multiple sclerosis (RRMS). CUAL is defined as: new gadolinium [Gd]-enhanced lesions on T1-weighted, or new or enlarging lesions on T2-weighted MRI scans, without double counting.
Inclusion criteria
- Relapsing-Remitting Multiple Sclerosis,Recidivující roztroušená skleróza